Roscovitine, a CDK5 Inhibitor, Alleviates Sevoflurane-Induced Cognitive Dysfunction via Regulation Tau/GSK3β and ERK/PPARγ/CREB Signaling

Area of Science:

• Neuroscience
• Anesthesiology
• Molecular Biology

Background:

• Repeated exposure to anesthesia in children may lead to cognitive impairment.
• Sevoflurane is a common anesthetic in pediatric surgery.
• The precise mechanism of sevoflurane-induced cognitive dysfunction involving cyclin-dependent kinase 5 (CDK5) is not fully understood.

Purpose of the Study:

• To investigate the mechanism by which CDK5 mediates sevoflurane-induced cognitive dysfunction.
• To evaluate the potential neuroprotective effects of CDK5 inhibition.

Main Methods:

• Primary hippocampal neurons were isolated from neonatal mice.
• Six-day-old wild-type mice were exposed to sevoflurane and treated with the CDK5 inhibitor roscovitine.
• Cognitive function was assessed using the Morris water maze, and neuronal damage was evaluated via immunohistochemistry.

Main Results:

• Sevoflurane exposure activated CDK5, leading to increased neuronal damage.
• CDK5 activation induced Tau/glycogen synthase kinase (GSK) 3β and suppressed ERK/PPARγ/CREB signaling.
• Roscovitine administration inhibited CDK5, alleviating sevoflurane-induced neuronal damage and cognitive deficits.

Conclusions:

• CDK5 inhibition with roscovitine demonstrates neuroprotective effects against sevoflurane-induced neuronal injury.
• The protective mechanism involves the modulation of Tau/GSK3β and ERK/PPARγ/CREB signaling pathways.
• Targeting CDK5 may be a therapeutic strategy to mitigate anesthesia-related cognitive dysfunction.